Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 12.56 -3.83% -0.50
SYRS closed down 3.83 percent on Friday, April 20, 2018, on 1.32 times normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical SYRS trend table...

Date Alert Name Type % Chg
Apr 20 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Apr 20 Bollinger Band Squeeze Range Contraction 0.00%
Apr 20 Upper Bollinger Band Walk Strength 0.00%
Apr 19 MACD Bearish Signal Line Cross Bearish -3.83%
Apr 19 Bollinger Band Squeeze Range Contraction -3.83%
Apr 19 Upper Bollinger Band Walk Strength -3.83%
Apr 19 BB Squeeze + Upper Band Touch Range Contraction -3.83%
Apr 19 Outside Day Range Expansion -3.83%
Apr 19 Upper Bollinger Band Touch Strength -3.83%
Apr 18 Bollinger Band Squeeze Range Contraction -7.99%

Older signals for SYRS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Is SYRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 24.38
52 Week Low 6.3
Average Volume 178,813
200-Day Moving Average 14.2876
50-Day Moving Average 11.843
20-Day Moving Average 12.8925
10-Day Moving Average 13.148
Average True Range 0.6609
ADX 23.82
+DI 16.29
-DI 18.12
Chandelier Exit (Long, 3 ATRs ) 11.8773
Chandelier Exit (Short, 3 ATRs ) 14.0127
Upper Bollinger Band 13.6238
Lower Bollinger Band 12.1612
Percent B (%b) 0.27
BandWidth 11.34458
MACD Line 0.3266
MACD Signal Line 0.3974
MACD Histogram -0.0708
Fundamentals Value
Market Cap 329.83 Million
Num Shares 26.3 Million
EPS -2.11
Price-to-Earnings (P/E) Ratio -5.95
Price-to-Sales 289.82
Price-to-Book 4.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.75
Resistance 3 (R3) 13.83 13.53 13.55
Resistance 2 (R2) 13.53 13.22 13.48 13.48
Resistance 1 (R1) 13.04 13.04 12.89 12.96 13.42
Pivot Point 12.74 12.74 12.66 12.69 12.74
Support 1 (S1) 12.25 12.43 12.10 12.17 11.70
Support 2 (S2) 11.95 12.25 11.90 11.64
Support 3 (S3) 11.46 11.95 11.57
Support 4 (S4) 11.38